#85 Research Authority
Peer-reviewed research curated for clinical relevance and evidence quality.
Recent research digest. 40 of 40 most recent studies from our monitored feeds.
Canadian real-world evidence: observational 24-week outcomes for health care practitioner authorized cannabis.
Yang Brian et al.
Canadian journal of pain = Revue canadienne de la douleur • 2026
I don’t have access to the complete abstract or results section needed to provide an accurate summary of the key findings. The text appears to be cut off at the methods section. To generate the clinical summary you’ve requested, I would need information about the actual outcomes reported, such as: – Whether cannabis improved pain, sleep, anxiety, and depression – By how much these measures improved – Any safety concerns noted Could you provide the complete abstract including the results and conclusions sections?
Prevalence, Associations and Comorbidity of Cannabis Use and Cannabis Use Disorders in the Australian National Mental Health Surveys From 2007 to 2020-22.
Wilson Jack et al.
Drug and alcohol review • 2026
# Clinical Summary This study tracked cannabis use and cannabis use disorder in Australian adults across two national surveys (2007 and 2020-22), finding changes in prevalence rates and identifying which populations were most affected as cannabis products became more potent. The research revealed associations between cannabis use and other mental health conditions, highlighting increasing public health concerns as cannabis policies liberalized over this 15-year period.
Cannabis and Mental Health: A Review.
Kansagara Devan et al.
JAMA internal medicine • 2026
# Clinical Summary Cannabis use is widespread among people with mental health disorders, but scientific evidence does not support its effectiveness for treating conditions like PTSD and likely carries significant risks of adverse effects. Clinicians should be aware that while patients often self-medicate with cannabis for mental health symptoms, clear therapeutic benefits remain unproven and potential harms warrant caution in clinical practice.
Cannabidiol-hyaluronic acid combination delivered rectally for attenuating abacterial prostatitis symptoms: Single-arm open-label pilot clinical trial.
Student Vladimir et al.
Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia • 2026
# Clinical Summary This pilot study tested whether nightly rectal suppositories containing cannabidiol and hyaluronic acid could reduce symptoms in 16 men with chronic prostatitis and pelvic pain. The treatment approach combined anti-inflammatory and tissue-protective properties to target pain and discomfort associated with this long-term urological condition.
Could the telescoping effect and comorbidity with substance use disorders account for sex differences in the processes and therapeutic outcomes? A latent-class moderation analysis.
Dacosta-Sánchez Daniel et al.
Drug and alcohol dependence • 2026
# Clinical Summary This study examined how sex differences affect substance use disorder treatment outcomes, particularly looking at whether women progress faster through addiction stages (telescoping effect) and how this interacts with other mental health conditions. The research found that women’s treatment responses vary based on how quickly their substance use progressed and what other psychiatric disorders they have, suggesting that treatment protocols need to account for these sex-specific patterns rather than using one-size-fits-all approaches designed around male patients.
The Influence of CBD and THC on Hepatic Enzymes of the Human Cytochrome P450 Complex Family: A Systematic Literature Review.
Dos Santos Mariana Candeias et al.
European journal of drug metabolism and pharmacokinetics • 2026
# Clinical Summary CBD and THC, the main active compounds in cannabis, can affect how the liver breaks down many common medications by altering the activity of liver enzymes called cytochrome P450 enzymes. This interaction is clinically important because these liver enzymes are responsible for metabolizing about 80% of all prescription drugs, meaning cannabis use could potentially change how effective or safe certain medications are.
Cannabis Use Among Individuals Treated with Medication for Opioid Use Disorder: Correlates, Patterns, and Motivations for Use.
Leyde Sarah E et al.
Substance use & addiction journal • 2026
# Clinical Summary This study found that cannabis use is common among people taking medications for opioid addiction, with frequent users (those using 3 or more days per week) having distinct demographic and clinical characteristics compared to less frequent users. The research identified specific factors and motivations associated with regular cannabis use in this patient population, which could help inform treatment planning and support strategies.
Clinical Outcomes and Patient Profiles in the UK Medical Cannabis Registry: A k-Means Clustering Analysis.
Erridge Simon et al.
Journal of clinical pharmacology • 2026
# Clinical Summary This study analyzed data from patients in the UK Medical Cannabis Registry to identify distinct patterns of how cannabis-based medicines affected quality of life over two years using statistical clustering methods. The research aimed to determine which baseline patient characteristics could predict who would benefit most from cannabis-based medicinal products for various medical conditions.
Investigating the effectiveness and adverse events of medicinal cannabis for patients with muscle spasticity or spasms.
Nastatos Xenia L et al.
The Journal of pharmacology and experimental therapeutics • 2026
# Clinical Summary This study examined whether medicinal cannabis products could effectively reduce muscle spasticity and spasms in 150 patients who reported their symptoms and quality of life outcomes over time. The research tracked patient-reported improvements and side effects to determine if cannabis might be a better treatment option than conventional medications, which often have limited effectiveness or cause troublesome side effects.
The prevalence of cannabis use pre-versus post-cannabis legalization in Canada by mental health status: findings from national repeat cross-sectional surveys.
Rundle Samantha et al.
Lancet regional health. Americas • 2026
# Clinical Summary This Canadian study found that cannabis use increased significantly after legalization in 2018, particularly among people with mental health conditions, suggesting that legal availability may disproportionately affect vulnerable populations. The findings highlight the need for targeted public health strategies and monitoring of cannabis use patterns in individuals with mental health disorders to mitigate potential harms from increased access.
Cannabis use among Canadian veterans: associations with the use of other substances, chronic pain conditions, mental disorders, suicide behaviours, and help-seeking.
Taillieu Tamara L et al.
Journal of cannabis research • 2026
# Clinical Summary This study examines cannabis use patterns among Canadian veterans and finds it is associated with higher rates of mental health conditions like PTSD, chronic pain, and suicidal behaviors compared to non-using veterans. Veterans who use cannabis also demonstrate lower rates of help-seeking despite experiencing greater health burdens, suggesting a need for more accessible and targeted mental health and substance use services for this population.
Parental sociodemographic profiles in relation to mental health, cannabis use motives, and cannabis use behaviors among a sample of US young adult parents.
Romm Katelyn F et al.
Addictive behaviors • 2026
# Clinical Summary This study identified distinct sociodemographic profiles among young adult parents and found that certain profiles were associated with higher rates of past-month cannabis use and specific mental health symptoms like depression and anxiety. The research suggests that parental cannabis use patterns vary significantly by social and demographic characteristics, with mental health symptoms and use motivations potentially playing important roles in explaining these differences.
Breastfeeding and Developmental Outcomes in Infants with Prenatal Cannabis Exposure: A Retrospective Cohort Study.
Nidey Nichole et al.
Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine • 2026
# Clinical Summary This study found that among infants exposed to cannabis during pregnancy, breastfeeding was associated with better developmental outcomes compared to formula feeding. The findings suggest that breastfeeding may provide protective benefits that outweigh theoretical risks from cannabis exposure through breast milk, supporting continued breastfeeding recommendations for mothers who used cannabis prenatally.
The relationship between maternal cannabis use disorder diagnosis and the development of retinopathy of prematurity.
Tran Melanie D et al.
Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus • 2026
# Clinical Summary This study found that preterm infants born to mothers with cannabis use disorder during pregnancy had comparable rates of retinopathy of prematurity (a serious eye condition affecting premature infants) compared to infants born to mothers without cannabis use disorder. The research suggests that maternal cannabis use disorder diagnosis alone may not be an independent risk factor for developing this vision-threatening complication in very premature infants.
Accidental cannabis intoxications in toddlers: what to expect? A case report.
Wagnez Lorena et al.
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie • 2026
Accidental cannabis poisoning in young children can be challenging to diagnose because healthcare providers must first suspect it as a cause and recognize the specific symptoms of cannabis intoxication in toddlers. Proper clinical management and awareness of cannabis exposure risks are important for treating unintentional cannabis ingestion in young children.
Sexual diversity, adolescent mental health, and adult cannabis use: Longitudinal associations through cannabis use motives.
London-Nadeau Kira et al.
Addictive behaviors • 2026
# Clinical Summary Adolescent depression symptoms predicted increased cannabis use in early adulthood, with this relationship potentially mediated by using cannabis to cope with negative emotions, particularly among sexually diverse individuals. Anxiety symptoms in adolescence did not show the same predictive relationship with adult cannabis use across sexual orientation groups.
Identifying missed prevention opportunities: maternal and congenital syphilis in hospital records and birth certificates in California from 2011 to 2021.
Frankeberger Jessica et al.
Journal of perinatology : official journal of the California Perinatal Association • 2026
# Clinical Summary This study found that approximately 0.06% of California births from 2011 to 2021 had congenital syphilis despite maternal syphilis being documented, indicating that many cases were not prevented even when maternal infection was known. Mothers with public insurance and tobacco use were at higher risk for delivering infants with congenital syphilis, suggesting that prevention opportunities were being missed in vulnerable populations.
Cannabis Use for Chronic Pain in Sickle Cell Disease: A Scoping Review.
Jackson Simone B et al.
Pain management nursing : official journal of the American Society of Pain Management Nurses • 2026
# Clinical Summary This scoping review examined the evidence for cannabis and cannabinoid use to treat pain in adults with sickle cell disease, following systematic review guidelines to evaluate effectiveness and identify gaps in the research. The review synthesized findings across multiple databases to assess how cannabis impacts pain outcomes in this patient population and highlight areas needing further investigation.
Characteristics associated with alcohol and cannabis-related impaired risky driving and riding behaviors among adolescents.
Tran Steven et al.
Traffic injury prevention • 2026
# Clinical Summary Adolescents who use alcohol and cannabis are at significantly increased risk for riding with impaired drivers and reporting willingness to drive under the influence, with peer influences and lower self-efficacy for refusing risky situations being key contributing factors. Parental involvement and adolescents’ perception of driving risks were protective factors that reduced the likelihood of these dangerous driving behaviors.
Effect of Nonmedical Cannabis Legalization and Exposure to Retail Stores on Cannabis Harms : A Quasi-experimental Study.
Friesen Erik Loewen et al.
Annals of internal medicine • 2026
# Clinical Summary This Canadian study found that higher exposure to cannabis retail stores was associated with increased emergency department visits for cannabis-related harms in Ontario between 2017 and 2022. The findings suggest that limiting the density of cannabis retail locations may help reduce cannabis-related health harms in the population, similar to strategies used for alcohol and tobacco.
Substance use and menopausal hormone therapy: Treatment initiation and interruption among US women with and without HIV, 2008-2019.
Knittel Andrea K et al.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics • 2026
# Clinical Summary Women with substance use and moderate-to-severe hot flashes were less likely to start menopausal hormone therapy compared to those without substance use, suggesting potential disparities in treatment access or prescribing patterns. This difference was observed among both HIV-positive and HIV-negative women in a diverse US cohort studied from 2008 to 2019.
Neuroprotective Role of Cannabinoid CB1 and GPR55 Receptors in a Cell Model of Multiple Sclerosis.
Martínez-Pinilla Eva et al.
Molecular neurobiology • 2026
# Clinical Summary Researchers investigated how cannabinoid receptors CB1 and GPR55 protect nerve cells in a laboratory model of multiple sclerosis, focusing on their ability to promote cell survival and support the myelin-producing cells that are damaged in MS. The study suggests that activating these receptors through the endocannabinoid system could offer new therapeutic approaches that directly protect neurons and support myelin repair, potentially addressing limitations of current MS treatments that mainly suppress immune
CBD, cannabis, or both? Examining use patterns and associated factors among U.S. youth and adults.
Dai Hongying Daisy et al.
Addictive behaviors • 2026
# Clinical Summary This study analyzed national survey data from over 56,000 U.S. youth and adults to identify distinct patterns of cannabis and CBD use, finding that these substances are used in various combinations rather than exclusively. The researchers identified specific demographic, social, and health factors that predict whether individuals use neither substance, only cannabis, only CBD, or both products together.
Correlates of Derived Cannabis Product Awareness, Knowledge, Use, and Use Intentions Among Young Adults.
LoParco Cassidy R et al.
Health education & behavior : the official publication of the Society for Public Health Education • 2026
# Clinical Summary This study found that among young adults, awareness and knowledge of chemically synthesized cannabis products (like delta-8 THC) varied by demographic factors and were associated with both current use and intentions to use these products in the future. The results suggest that demographic characteristics and level of product knowledge are key predictors of whether young adults use or plan to use derived cannabis products.
Insights Into Cannabis and Cannabinoids: Chemical Properties, Legal Perspectives, and Therapeutic Applications.
Vihal Samar et al.
Chemistry & biodiversity • 2026
Cannabis contains over 500 chemical compounds including cannabinoids, terpenes, and flavonoids that have potential therapeutic effects for conditions such as chronic pain, epilepsy, cancer, mental health disorders, and inflammation. The review integrates historical use, chemical analysis, clinical evidence, and regulatory frameworks to assess both the medical applications and legal status of cannabis and its components.
Rates and predictors of postdischarge opioid-free analgesia after elective colorectal surgery: A prospective cohort study.
Pook Makena et al.
Surgery • 2026
# Clinical Summary This study found that a meaningful proportion of colorectal surgery patients successfully manage postoperative pain without opioids after discharge, challenging the assumption that opioids are necessary for all patients. Patient and surgical care characteristics including use of multimodal pain management strategies, regional anesthesia techniques, and certain patient demographics were identified as predictors of achieving opioid-free recovery.
UK Medical Cannabis Registry: a case series analysing clinical outcomes of medicinal cannabis therapy for fibromyalgia.
Varadpande Madhur et al.
Clinical rheumatology • 2026
# Clinical Summary This UK study tracked fibromyalgia patients treated with medicinal cannabis products using a patient registry, measuring changes in pain and quality of life outcomes along with any side effects experienced. The research aimed to provide clinical evidence on whether cannabis-based medicines could safely help reduce the widespread chronic pain and associated depression or anxiety that commonly affects fibromyalgia patients.
The Impact of Dual Cannabis and Tobacco Smoking in Young Patients With Lung Cancer: Results From the Prospective “Environment and Lung Cancer” Study.
Pradère Pauline et al.
Chest • 2026
I don’t have access to the complete abstract or results section needed to provide accurate key findings from this study. To give you an accurate clinical summary, I would need to see the study’s actual results, conclusions, or findings section. If you can share the results portion of the abstract or the key findings, I’d be happy to provide the 2-sentence summary you requested.
Reducing severe breathlessness with dronabinol in the group of patients with severe and very severe chronic obstructive pulmonary disease (BONG): a randomised, double-blinded, placebo-controlled, crossover study in an outpatient clinic in Denmark – a study protocol.
Wolsing Sofie Krogh et al.
BMJ open • 2026
# Clinical Summary This study is a research protocol investigating whether dronabinol (a synthetic cannabis compound) can reduce severe breathlessness in patients with advanced chronic obstructive pulmonary disease who remain symptomatic despite standard treatment. The trial will randomly assign 30 patients to receive either dronabinol or placebo in a crossover design at a Danish pulmonary clinic to determine if the medication provides relief.
A longitudinal quasi-experimental study of a pedagogical approach to supporting undergraduate well-being and mental health: digital interdisciplinary accredited elective mental health literacy university course.
Duffy Anne et al.
BJPsych open • 2026
# Clinical Summary I cannot provide a summary of the key findings because the abstract does not include a results section. The abstract describes the study’s background, aims, and methods, but does not report what outcomes were actually found or whether the mental health literacy course improved student well-being. To create an accurate 2-sentence clinical summary, I would need access to the full paper’s results section.
Cannabis Use in a Community-Based Sample of Adults Diagnosed With ADHD: Prevalence, Impact on Symptoms, and Stimulant Side Effects.
Ryan Jennie E et al.
Journal of attention disorders • 2026
# Clinical Summary This study found that cannabis use is common among adults with ADHD, with users reporting it helps manage both ADHD symptoms and side effects from prescription stimulant medications. The research highlights a potential self-medication pattern in which adults with ADHD may turn to cannabis to supplement or mitigate effects of their standard ADHD treatments.
Machine learning identifies traumatic experiences as being associated with auditory verbal hallucinations in both a non-clinical population and individuals diagnosed with psychosis.
Ostojic Dijana et al.
Psychiatry research • 2026
# Clinical Summary This study used machine learning to analyze data from over 130,000 UK Biobank participants and found that traumatic experiences were the strongest predictor of auditory verbal hallucinations in both people with psychosis and the general population. The findings suggest that trauma exposure is a common risk factor for hearing voices, regardless of whether someone has been diagnosed with a psychotic disorder.
Lifetime Adversity Among Individuals With Early Phase Psychosis and Comorbid Substance Misuse.
Patterson Victoria C et al.
Early intervention in psychiatry • 2026
# Clinical Summary This study examined how often people with early psychosis experience both traumatic life events and substance misuse together, finding that these problems frequently overlap in this population. The research expanded the definition of adversity beyond childhood abuse to include psychosis-related experiences like threatening hallucinations, revealing a more complete picture of the hardships faced by these individuals.
Talking About Cannabis: Perspectives of First Episode Psychosis Care Participants and Parents.
Lucksted Alicia et al.
Journal of dual diagnosis • 2026
# Clinical Summary Young people with first-episode psychosis and their parents want more open and targeted conversations about cannabis use, as current discussions often lack specificity or fail to address individual concerns and motivations for use. Healthcare providers should tailor cannabis counseling to each patient’s situation and involve family members to improve engagement and outcomes in early psychosis treatment programs.
ACMT Position Statement Revision: Preventing Cannabis Exposures in Children.
Hendrickson Robert et al.
Journal of medical toxicology : official journal of the American College of Medical Toxicology • 2026
Cannabinoid Hyperemesis Syndrome in Adolescents: A Single Institution Case Series.
Vega Castellvi Claudia et al.
Pediatric emergency care • 2026
# Clinical Summary This study describes a pediatric case series of cannabinoid hyperemesis syndrome (CHS), a condition characterized by repeated vomiting caused by chronic heavy cannabis use that is frequently missed on initial diagnosis. The findings highlight that CHS leads to significant unnecessary medical testing and healthcare visits, while also identifying associated mental health issues and documenting how different treatments affect patient outcomes.
The Need for Oversight of Unflavored Cannabis Drink Mixers.
Howard Caroline et al.
Pediatrics • 2026
Call for action: misinformation about Tourette syndrome from major media network.
Müller-Vahl Kirsten R et al.
European child & adolescent psychiatry • 2026
Health Care Utilization and Developmental Delay Among Infants Exposed to Cannabis In Utero.
Raffa Brittany J et al.
Academic pediatrics • 2026
# Clinical Summary Infants exposed to cannabis in utero had higher rates of emergency department visits and developmental delay diagnoses compared to unexposed infants during their first two years of life. Cannabis-exposed infants also showed lower attendance at well-child care visits, which may have contributed to delayed detection and diagnosis of developmental problems.
Latent Classes of Substance Use in Young Adult Survivors of Child Maltreatment and Adversity: A 20-Year Prospective Investigation.
Morelli Nicholas M et al.
Child maltreatment • 2026
# Clinical Summary Young adults who experienced child abuse or neglect in childhood were assessed at age 24 for their substance use patterns, revealing distinct groups with different levels of risk based on their exposure to adverse childhood experiences. The study identified multiple substance use trajectories during the transition to adulthood, showing that early maltreatment and accumulated adversity were associated with varying patterns of drug and alcohol use in young adulthood.
Digest generated March 16, 2026 at 06:35 PM